AV-203 - AVEO, CANbridge Life Sciences
AVEO Oncology: Corporate Presentation (Aveo Oncology) - Aug 13, 2015 - Anticipated patent expiry for composition of matter in 2031; Anticipated patent expiry for NRG-1 biomarker in 2032 
Anticipated patent expiry • Oncology
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-irhome
 
Aug 13, 2015
 
.
 
99e59525-ecbf-40d6-9676-83a443821802.jpg